Strides Pharma Science Ltd Q4 FY2024 Concall Summary

Source transcript PDF: https://assets.stockscans.in/docs/pfbd1eznf1d1m1nsp4527rd0.pdf

Key Takeaways


US Business: The $400 Million Engine

Arun Kumar: "The current strategy of niche limited competition kind of limits our growth to $400 million. That's our aspirational growth. We are now very confident we can achieve that."

OneSource (Stelis) & the Demerger


Growth Levers Beyond the US

Arun Kumar: "Clearly, the Biosecurity Act has been diluted quite significantly and there is a 7 to 8 year window for companies dependent on China to find solutions or alternative solutions. But we are seeing significant amount of new RFPs for biologics. And I think the China Plus One on the biologics is playing through."

Margins & Cost Structure

Arun Kumar: "We probably have about 200 to 250 basis points of margin expansion through cost improvements and completion of network optimization. And that is why we said our dream goal is to get to our 21.5% peak EBITDA percentage-wise. And we think we can do that in the next 12 to 16 to 18 months."

Balance Sheet & Capital Allocation


Guidance & Commitments

CommitmentSpecificsTimeline
Overall revenue growth12% to 15% growth, bulk in H2FY25
EBITDA (company level)INR 950 crores to INR 1,000 croresFY25
EBITDA (retained business)INR 750 crores to INR 800 croresFY25
US business revenue$285 million to $300 millionFY25
US business long-term target$400 million sizeNext 2 to 3 years
Debt reductionReduce debt by INR 500 crores after INR 200 crores capexFY25
Debt-to-EBITDA ratioUnder 2xFY25
Debt-freeZero debt3 to 4 years
EBITDA marginReturn to 21%+ (21.5% peak)Next 12 to 18 months
OneSource profitabilityProfitable divisionFY25
OneSource NCLT filingCommence filingNext couple of weeks
OneSource revenue target$400 million3 years from listing
OneSource capacity expansion4 crore to 20 crore drug-device combination unitsFY26
Nasal spray first filingFirst filingFY25
505(b)(2) first filingFirst filingMiddle of next financial year
GLP-1 commercial suppliesFirst commercial supplies commenceFY25
Liraglutide launchLaunchH2 FY25
Orbicular platform completionEntire platform program completedNext 12 months
Demerger completionCourt process (3–4 quarters) plus ~60 days for listingFiling this quarter

Key Metrics

MetricQ4 FY24
RevenueShade under $500 million for FY24
Gross margin60.7% in Q4, sustainable plus/minus 2%; FY24 consistent between 59% and 60%
EBITDA margin19.3%, moving up from 16%
Adjusted PATAround INR200 crores for former business
US business revenue$250 million at the higher end of the outlook, bang on target
US business FY25 revenue guidance$285 million to $300 million
Other regulated markets growth19%, almost 20%
Access and growth markets growthAlmost about 25%
Debt-to-EBITDA ratio2.72x
Free cash flowAlmost INR700 crores, almost 95% of EBITDA-to-cash conversion ratio
ROCE exit run rate15%
Gross block to asset turnoverAlmost 5x
US business failure to supplySub-$200,000 for a $250 million business
Drug device combination capacity4 crore units, expanding to 20 crore units in FY26
Stelis (OneSource) profitabilityFirst-ever quarter with a breakeven